Joey DeBruin Profile
Joey DeBruin

@joey_debruin

Followers
5K
Following
8K
Media
529
Statuses
7K

Ex-neuroscientist, ex-chef, ex-plorer. Founder @robodottech — building AI for biotech. Writing @ https://t.co/zy6BhLXPtV ✍️

Santa Monica, California
Joined March 2015
Don't wanna be here? Send us removal request.
@joey_debruin
Joey DeBruin
3 months
Things have changed a ton for us over the past month — we've gone from quietly building the first version of our AI platform for biotech to being totally underwater trying to onboard new companies. Outside of product stuff what's bottlenecking us now is mapping out the details.
1
2
6
@joey_debruin
Joey DeBruin
3 months
Seeing @sariazout bring @wwwsublimeapp to life continues to be my main source of inspiration on how to build something that works for millions of people but that only you could build.
@sariazout
sari azout
3 months
so thrilled to share that after 18 months in private beta, @wwwsublimeapp opens its doors to everyone today (!!). save one idea.discover 100 more. it all starts with a single save. come play.sublime (dot) app
1
3
12
@joey_debruin
Joey DeBruin
3 months
If you're in the oncology/biopharma world our AI agents are building a 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐝𝐚𝐭𝐚𝐬𝐞𝐭 𝐨𝐧 𝐀𝐀𝐂𝐑 𝟐𝟎𝟐𝟓 abstracts with 𝟔𝟎+ 𝐟𝐢𝐞𝐥𝐝𝐬 𝐨𝐟 𝐦𝐞𝐭𝐚𝐝𝐚𝐭𝐚. Happy to share free access for anyone doing something interesting with it💡. Includes:
1
1
5
@joey_debruin
Joey DeBruin
4 months
Personally, I’m most intrigued by the longitudinal target viability—what can we learn from candidates that drop off the map? This is a challenge only AI’s processing power can tackle.
0
0
2
@joey_debruin
Joey DeBruin
4 months
Next step is to integrate this workflow into our platform to fine tune the evals and get ready to run it on this year’s abstracts as soon as they drop. If anyone is interested in the raw data or a more specific deep dive, reach out!.
2
0
3
@joey_debruin
Joey DeBruin
4 months
The agents:.- Extracted data on therapeutic area, indication, target, payload, clinical stage, etc. - Focused exclusively on ADCs to analyze trends over time. - Augmented findings with additional online research.- Generated a list of suggested follow-up analyses
Tweet media one
1
0
1
@joey_debruin
Joey DeBruin
4 months
Over the weekend, I had a team of AI “consultants” digest 13,000 abstracts from the past 2 years of AACR— and produce a deep-dive report on the progress of ADCs.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
1
6
@joey_debruin
Joey DeBruin
4 months
So the most notable announcements for me are how much tooling they are building on top of the models via the APIs, which would seemingly cannibalize their ChatGPT value unless they ultimately see those as one product.
0
0
1
@joey_debruin
Joey DeBruin
4 months
From this view, it's obvious why OpenAI wouldn't kill the APIs or ChatGPT — the goal is to continue pulling them together as computers can behave increasingly like humans. What I would expect goes away is the drive to serve developers with low cost models.
1
0
1
@joey_debruin
Joey DeBruin
4 months
The delta between ChatGPT and what's accessible via the APIs is shrinking fast (and clearly intentionally). At some point, you could imagine they just have a single ChatGPT-like product that's accessible one way for humans (app) and another way for agents (API).
1
0
1
@joey_debruin
Joey DeBruin
4 months
It's pretty obvious now that you need a lot more than just the models — you need the ability to search, make purchases, maybe eventually even interact in the physical world. ChatGPT already has a ton of features on top of the underlying model.
1
0
0
@joey_debruin
Joey DeBruin
4 months
OpenAI clearly wants to be a consumer company. But I think they want to be a consumer company for all human-like intelligences, not just humans.
1
0
1
@joey_debruin
Joey DeBruin
4 months
I rarely disagree with @benthompson but I think this framing confuses APIs with access to underlying models.
@stratechery
Stratechery
4 months
3-12-2025 ($) . •OpenAI API Updates.•Steelmanning the API Business.•The Problem With Both.
1
0
3
@joey_debruin
Joey DeBruin
4 months
I was standing at a baggage claim in Oregon last week, shooting the breeze with a stranger and talking about the work we do. Next thing I know we’re talking about his cancer, and the somewhat unorthodox ways doctors are (hopefully) helping him survive it. It just reminded me
Tweet media one
0
0
1
@joey_debruin
Joey DeBruin
4 months
Time to stop spending thousands on consultant reports for these conferences, right?.
0
0
1
@joey_debruin
Joey DeBruin
4 months
If you want the raw data or a fresh perspective, DM me. I’d love to chat with AACR/ASCO attendees on leveraging new abstracts to get more out of the conference.
1
0
2
@joey_debruin
Joey DeBruin
4 months
I’ve done the same for every therapeutic area—from CAR‑T to bispecific antibodies. And it only took a day and $20 of compute 🤯.
1
0
1
@joey_debruin
Joey DeBruin
4 months
Example: A diagram mapping which companies & academic labs are targeting specific antigens with ADC (antibody‑drug conjugate) therapies in 2024.
Tweet media one
Tweet media two
1
0
2
@joey_debruin
Joey DeBruin
4 months
What happens when you set AI agents loose on 20,000 AACR abstracts from the past 3 years? You get . a lot of insights.
Tweet media one
1
1
7
@joey_debruin
Joey DeBruin
4 months
I'm putting together a few curated, casual dinners in LA for senior leaders in biotech BD/R&D + AI experts to talk about what the go to market process will (or should) look like in biotech in 2-3 years. If you know someone we should invite, let me know! Bonus is getting to.
2
0
4